{
    "nctId": "NCT02057029",
    "briefTitle": "Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer",
    "officialTitle": "Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Early Stage Estrogen Receptor (ER) Positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 96,
    "primaryOutcomeMeasure": "Patient Endocrine Therapy Questionnaires",
    "eligibilityCriteria": "Inclusion Criteria:\n\nEach patient must meet all of the following criteria in order to be considered for enrollment:\n\n* Histologically confirmed ER positive, stage I-III breast cancer who have been treated with curative intent and completed at least four years of adjuvant endocrine therapy.\n* Life expectancy \u2265 5 years.\n* Must be able to provide informed consent.\n* Willing to consider continuation of endocrine therapy beyond 5 years.\n\nExclusion Criteria:\n\n* A patient must not be enrolled if any contraindication exists for extended adjuvant endocrine therapy as identified by the treating oncologist.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}